JP7667573B2 - Ｋｃｎｔ１阻害剤および使用する方法 - Google Patents

Ｋｃｎｔ１阻害剤および使用する方法 Download PDF

Info

Publication number
JP7667573B2
JP7667573B2 JP2021564995A JP2021564995A JP7667573B2 JP 7667573 B2 JP7667573 B2 JP 7667573B2 JP 2021564995 A JP2021564995 A JP 2021564995A JP 2021564995 A JP2021564995 A JP 2021564995A JP 7667573 B2 JP7667573 B2 JP 7667573B2
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
formula
compound
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021564995A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022531388A (ja
JP2022531388A5 (cg-RX-API-DMAC10.html
Inventor
ボテッラ， ガブリエル マルティネス
アンドリュー マーク グリフィン，
ポール エス． チャリフソン，
キラン レディ，
マイケル クリストファー マシュー カーリグ，
ブライアン エドワード マロン，
Original Assignee
プラクシス プレシジョン メディシンズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プラクシス プレシジョン メディシンズ， インコーポレイテッド filed Critical プラクシス プレシジョン メディシンズ， インコーポレイテッド
Publication of JP2022531388A publication Critical patent/JP2022531388A/ja
Publication of JP2022531388A5 publication Critical patent/JP2022531388A5/ja
Priority to JP2025062493A priority Critical patent/JP2025102975A/ja
Application granted granted Critical
Publication of JP7667573B2 publication Critical patent/JP7667573B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2021564995A 2019-05-03 2020-05-01 Ｋｃｎｔ１阻害剤および使用する方法 Active JP7667573B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025062493A JP2025102975A (ja) 2019-05-03 2025-04-04 Ｋｃｎｔ１阻害剤および使用する方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962842849P 2019-05-03 2019-05-03
US62/842,849 2019-05-03
US202062982864P 2020-02-28 2020-02-28
US62/982,864 2020-02-28
PCT/US2020/031046 WO2020227101A1 (en) 2019-05-03 2020-05-01 Kcnt1 inhibitors and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025062493A Division JP2025102975A (ja) 2019-05-03 2025-04-04 Ｋｃｎｔ１阻害剤および使用する方法

Publications (3)

Publication Number Publication Date
JP2022531388A JP2022531388A (ja) 2022-07-06
JP2022531388A5 JP2022531388A5 (cg-RX-API-DMAC10.html) 2023-05-11
JP7667573B2 true JP7667573B2 (ja) 2025-04-23

Family

ID=73051241

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021564995A Active JP7667573B2 (ja) 2019-05-03 2020-05-01 Ｋｃｎｔ１阻害剤および使用する方法
JP2025062493A Pending JP2025102975A (ja) 2019-05-03 2025-04-04 Ｋｃｎｔ１阻害剤および使用する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025062493A Pending JP2025102975A (ja) 2019-05-03 2025-04-04 Ｋｃｎｔ１阻害剤および使用する方法

Country Status (17)

Country Link
US (1) US20220259193A1 (cg-RX-API-DMAC10.html)
EP (1) EP3962481A4 (cg-RX-API-DMAC10.html)
JP (2) JP7667573B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220016086A (cg-RX-API-DMAC10.html)
CN (2) CN120817941A (cg-RX-API-DMAC10.html)
AU (1) AU2020267356B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021022067A2 (cg-RX-API-DMAC10.html)
CA (1) CA3139063A1 (cg-RX-API-DMAC10.html)
CL (2) CL2021002877A1 (cg-RX-API-DMAC10.html)
CO (1) CO2021016471A2 (cg-RX-API-DMAC10.html)
EC (1) ECSP21087884A (cg-RX-API-DMAC10.html)
IL (1) IL287768A (cg-RX-API-DMAC10.html)
MX (1) MX2021013421A (cg-RX-API-DMAC10.html)
PE (1) PE20220016A1 (cg-RX-API-DMAC10.html)
SA (1) SA521430751B1 (cg-RX-API-DMAC10.html)
SG (1) SG11202112158YA (cg-RX-API-DMAC10.html)
WO (1) WO2020227101A1 (cg-RX-API-DMAC10.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12590083B2 (en) 2019-01-25 2026-03-31 University Of Virginia Patent Foundation Inhibitors of spinster homolog 2 (SPNS2) for use in therapy
EP4446314A3 (en) * 2019-05-03 2025-03-12 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
EP4110317B1 (en) * 2020-02-28 2025-11-19 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
WO2022056042A1 (en) * 2020-09-09 2022-03-17 University Of Virginia Patent Foundation Inhibitors of spinster homolog 2 (spns2) for use in therapy
US11773088B2 (en) 2020-11-02 2023-10-03 Praxis Precision Medicines, Inc. KCNT1 inhibitors and methods of use
TW202227424A (zh) * 2020-11-27 2022-07-16 大陸商瑞石生物醫藥有限公司 芳基或雜芳基取代５員芳雜環化合物及其用途
US20240043415A1 (en) * 2020-12-22 2024-02-08 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
EP4329735B1 (en) * 2021-04-29 2026-02-25 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
WO2022231872A1 (en) * 2021-04-29 2022-11-03 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
WO2023211850A1 (en) * 2022-04-25 2023-11-02 Praxis Precision Medicines, Inc. Kcnt1 inhibitors comprising an isoxazole or oxadiazole core and methods of use
EP4536644A4 (en) * 2022-06-08 2026-05-20 Praxis Prec Medicines Inc KCNT1 INHIBITORS COMPRISING AN ISOXAZOLE OR OXADIAZOLE NUCLEUS AND METHODS OF USE
CN116813505B (zh) * 2023-06-29 2025-09-02 爱斯特（成都）生物制药股份有限公司 一种制备o-甲基-n-苄氧羰基-l-高丝氨酸的方法
CN122555695A (zh) * 2023-11-29 2026-08-11 爱克堤欧生物科学股份有限公司 可用作kcnt1抑制剂的杂环化合物
WO2026082925A1 (en) 2024-10-18 2026-04-23 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of their use

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006014185A1 (en) 2004-02-18 2006-02-09 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
WO2014141104A1 (en) 2013-03-14 2014-09-18 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
WO2016053855A1 (en) 2014-09-29 2016-04-07 The Scripps Research Institute Sphingosine-1-phospate receptor modulators for treatment of cardiopulmonary disorders
WO2018187480A1 (en) 2017-04-04 2018-10-11 Praxis Precision Medicines, Inc. Compounds and their methods of use

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
TW200301698A (en) * 2001-12-21 2003-07-16 Bristol Myers Squibb Co Acridone inhibitors of IMPDH enzyme
JP2005060255A (ja) * 2003-08-20 2005-03-10 Nippon Nohyaku Co Ltd カルボキサミド類及びこれを有効成分とする有害生物防除剤
BRPI0713187A2 (pt) * 2006-07-20 2012-10-16 Mehmet Kahraman método de inibir rho-quinase, método de tratamento de doença mediada por rho-quinase, composto e composição farmacêutica
EP3275440B1 (en) * 2015-03-25 2022-05-04 National Center for Geriatrics and Gerontology Novel oxadiazole derivative and pharmaceutical containing same
JPWO2017170826A1 (ja) * 2016-03-30 2019-02-14 味の素株式会社 グルカゴン様ペプチド−１受容体作用増強活性を有する化合物
EP4110317B1 (en) * 2020-02-28 2025-11-19 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
KR20230005168A (ko) * 2020-03-23 2023-01-09 프락시스 프리시젼 메디신즈, 인크. Kcnt1 억제제 및 사용 방법
CN116075297A (zh) * 2020-07-06 2023-05-05 普拉西斯精密医药公司 Kcnt1抑制剂和使用方法
US11773088B2 (en) * 2020-11-02 2023-10-03 Praxis Precision Medicines, Inc. KCNT1 inhibitors and methods of use
US20240043415A1 (en) * 2020-12-22 2024-02-08 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
EP4329735B1 (en) * 2021-04-29 2026-02-25 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006014185A1 (en) 2004-02-18 2006-02-09 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
WO2014141104A1 (en) 2013-03-14 2014-09-18 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
WO2016053855A1 (en) 2014-09-29 2016-04-07 The Scripps Research Institute Sphingosine-1-phospate receptor modulators for treatment of cardiopulmonary disorders
WO2018187480A1 (en) 2017-04-04 2018-10-11 Praxis Precision Medicines, Inc. Compounds and their methods of use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
J. Braz. Chem. Soc.，2004年，Vol.15, No.4，p.603-607
Synthesis，2004年，No.10，p.1589-1594
Tetrahedron Letters，2001年，Vol.42，p.1495-1498

Also Published As

Publication number Publication date
JP2025102975A (ja) 2025-07-08
BR112021022067A2 (pt) 2022-05-17
IL287768A (en) 2022-01-01
JP2022531388A (ja) 2022-07-06
CN114269340A (zh) 2022-04-01
CA3139063A1 (en) 2020-11-12
KR20220016086A (ko) 2022-02-08
CL2021002877A1 (es) 2022-08-12
CN120817941A (zh) 2025-10-21
PE20220016A1 (es) 2022-01-11
CO2021016471A2 (es) 2022-04-08
EP3962481A4 (en) 2023-03-22
AU2020267356B2 (en) 2025-04-24
CL2024002067A1 (es) 2024-12-13
MX2021013421A (es) 2022-02-11
US20220259193A1 (en) 2022-08-18
ECSP21087884A (es) 2022-01-31
SG11202112158YA (en) 2021-12-30
SA521430751B1 (ar) 2024-02-01
AU2020267356A1 (en) 2022-01-06
EP3962481A1 (en) 2022-03-09
WO2020227101A1 (en) 2020-11-12

Similar Documents

Publication Publication Date Title
JP2025102975A (ja) Ｋｃｎｔ１阻害剤および使用する方法
EP3580220B1 (en) Aminotriazolopyridines as kinase inhibitors
EP3408268B1 (en) Benzimidazole derivatives as modulators of ror-gamma
EP3743430B1 (en) Aminopyrrolotriazines as kinase inhibitors
EP3704118B1 (en) Aminoimidazopyridazines as kinase inhibitors
JP7824664B2 (ja) Ｋｃｎｔ１阻害剤及び使用方法
JP7699836B2 (ja) Ｋｃｎｔ１阻害剤、および使用方法
JP2022530989A (ja) Ｋｃｎｔ１阻害剤および使用する方法
CN101801957A (zh) 吡啶酮gpr119g蛋白偶联受体激动剂
WO2014074675A1 (en) Heteroaryl substituted pyridyl compounds useful as kinase modulators
US20240043415A1 (en) Kcnt1 inhibitors and methods of use
US20250154139A1 (en) Pyridazinone compounds as trpa1 inhibitors
EP4499611B1 (en) Malt1 modulators and uses thereof
HK40069627A (en) Modulators of ror-gamma
EA042124B1 (ru) Аминоимидазопиридазины в качестве ингибиторов киназ
HK40001214B (en) Benzimidazole derivatives as modulators of ror-gamma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230428

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240806

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250206

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250305

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250404

R150 Certificate of patent or registration of utility model

Ref document number: 7667573

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150